INDP
HEALTHCAREIndaptus Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving INDP Today?
No stock-specific AI insight has been generated for INDP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.05
Fundamentals
Trading
INDP News
12 articles- Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarYahoo Finance·Dec 29, 2025
- Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source SummitYahoo Finance·Nov 17, 2025
- Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 12, 2025
- Wall Street Set to Open Higher Friday; Nonfarm Payrolls Fall Well Short of ForecastsYahoo Finance·Sep 5, 2025
- Indaptus Therapeutics Provides Clinical UpdateYahoo Finance·Sep 4, 2025
- Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment ConferenceYahoo Finance·Sep 2, 2025
- Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Aug 13, 2025
- Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and WarrantsYahoo Finance·Jul 1, 2025
- Indaptus Therapeutics Announces Reverse Stock SplitYahoo Finance·Jun 25, 2025
- Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and WarrantsYahoo Finance·Jun 13, 2025
- Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor TislelizumabYahoo Finance·Jun 2, 2025
- Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·May 14, 2025
All 12 articles loaded
Price Data
52-Week Range
$2.05
Fundamentals
Trading
About Indaptus Therapeutics Inc
Indaptus Therapeutics Inc. is a cutting-edge biotechnology firm focused on pioneering immunotherapies that aim to transform the landscape of cancer treatment. Utilizing a proprietary platform that enhances the immune system's capacity to identify and destroy tumor cells, the company is dedicated to increasing treatment efficacy and improving patient outcomes. With a robust portfolio of clinical candidates addressing critical unmet medical needs within oncology, Indaptus is strategically positioned for growth in an increasingly competitive market. Its dedication to scientific innovation and partnerships with leading research institutions highlights its potential as a transformative force in the biopharmaceutical sector.